Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.37 |
| ▸ | FDPS | P14324 | 3/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.35 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12939814 | 1.00 | TSHR (0.42) | TSHRLMNADNM1THRBOPRM1 | |
| SCHEMBL8644486 | 1.00 | TSHR (0.42) | TSHRLMNADNM1THRBOPRM1 | |
| SCHEMBL29525101 | 0.98 | TSHR (0.40) | TSHRLMNADNM1THRBOPRM1 | |
| SCHEMBL1960012 | 0.97 | TSHR (0.43) | TSHRLMNADNM1THRBOPRM1 | |
| Hydrochloric Acid SCHEMBL29189739 | 0.95 | TSHR (0.42) | TSHRLMNADNM1THRBOPRM1 | |
| Hydrochloric Acid SCHEMBL5480968 | 0.95 | TSHR (0.42) | TSHRLMNADNM1THRBOPRM1 | |
| SCHEMBL7158134 | 0.90 | TSHR (0.42) | TSHRLMNADNM1OPRM1 | |
| SCHEMBL24044418 | 0.90 | TSHR (0.46) | TSHRLMNADNM1THRBOPRM1 | |
| SCHEMBL13601912 | 0.90 | TSHR (0.46) | TSHRLMNADNM1THRBOPRM1 | |
| SCHEMBL985792 | 0.90 | TSHR (0.46) | TSHRLMNADNM1THRBOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113264915-A | Method for synthesizing 1- (1, 4-dioxaspiro [4,5] decane-8-yl) ethanone | 南京爱可德夫科技开发有限公司 | 2021-08-17 | — | — | CN | claimed |
| CN-113121781-A | Preparation method of self-repairable thermosetting film based on multi-component Ugi polymerization reaction and dynamic oxime urethane bond exchange | 西北工业大学 | 2021-07-16 | — | — | CN | claimed |
| EP-4384493-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2024-06-19 | — | — | EP | disclosed |
| WO-2024109923-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2024-05-30 | — | — | WO | disclosed |
| CN-118076581-A | Iron death modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-114315834-B | Imidazolone derivatives and their use in medicine | 成都百裕制药股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-116724024-A | Process for preparing platinib | 缆图药品公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-116669741-A | Polycyclic kinase inhibitors | 山东轩竹医药科技有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-116635380-A | PPARgamma modulators and methods of use | 卫材R&D管理有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-116406272-A | DNA-PK selective inhibitor and preparation method and application thereof | 首药控股(北京)股份有限公司 | 2023-07-07 | — | — | CN | disclosed |
| US-20230183222-A1 | 8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2023-06-15 | — | — | US | disclosed |
| WO-2017121647-A1 | 3-((HETERO-)ARYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2017-07-20 | — | — | WO | disclosed |
| WO-2017121646-A1 | 3-(CARBOXYETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2017-07-20 | — | — | WO | disclosed |
| WO-2017121649-A1 | 3-(CARBOXYMETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2017-07-20 | — | — | WO | disclosed |
| WO-2017121648-A1 | 3-((HETERO-)ARYL)-ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2017-07-20 | — | — | WO | disclosed |
| US-20170197971-A1 | 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2017-07-13 | — | — | US | disclosed |
| US-20170197970-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2017-07-13 | — | — | US | disclosed |
| US-8163775-B2 | Allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA SA (CH) | 2012-04-24 | — | — | US | disclosed |
| WO-2011036478-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2011-03-31 | — | — | WO | disclosed |
| US-5834499-A | TREATING GASTROINTESTINAL DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1998-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197970-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | TSHR 2261/4885LMNA 2991/4885DNM1 1385/4885 |
| US-20170197971-A1 | 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, PKD2 | TSHR 3065/4885LMNA 1276/4885DNM1 1621/4885 |
| US-20230183222-A1 | 8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | TSHR 2683/4885LMNA 2008/4885DNM1 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.